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Background: Dihydroneopterin aldolase (DHNA) catalyzes the conversion of 7,8-dihydroneopterin to 6-hydroxymethyl-
7,8-dihydropterin and also the epimerization of DHNP to 7,8-dihydromonapterin. Previously, we determined the crystal
structure of Staphylococcus aureus DHNA (SaDHNA) in complex with the substrate analogue neopterin (NP). We also
showed that Escherichia coli DHNA (EcDHNA) and SaDHNA have significantly different binding and catalytic properties
by biochemical analysis. On the basis of these structural and functional data, we proposed a catalytic mechanism
involving two proton wires.
Results: To understand the structural basis for the biochemical differences and further investigate the catalytic
mechanism of DHNA, we have determined the structure of EcDHNA complexed with NP at 1.07-Å resolution
[PDB:2O90], built an atomic model of EcDHNA complexed with the substrate DHNP, and performed molecular
dynamics (MD) simulation analysis of the substrate complex. EcDHNA has the same fold as SaDHNA and also forms
an octamer that consists of two tetramers, but the packing of one tetramer with the other is significantly different
between the two enzymes. Furthermore, the structures reveal significant differences in the vicinity of the active
site, particularly in the loop that connects strands β3 and β4, mainly due to the substitution of nearby residues.
The building of an atomic model of the complex of EcDHNA and the substrate DHNP and the MD simulation of
the complex show that some of the hydrogen bonds between the substrate and the enzyme are persistent,
whereas others are transient. The substrate binding model and MD simulation provide the molecular basis for the
biochemical behaviors of the enzyme, including noncooperative substrate binding, indiscrimination of a pair of
epimers as the substrates, proton wire switching during catalysis, and formation of epimerization product.
Conclusions: The EcDHNA and SaDHNA structures, each in complex with NP, reveal the basis for the biochemical
differences between EcDHNA and SaDHNA. The atomic substrate binding model and MD simulation offer insights
into substrate binding and catalysis by DHNA. The EcDHNA structure also affords an opportunity to develop
antimicrobials specific for Gram-negative bacteria, as DHNAs from Gram-negative bacteria are highly homologous
and E. coli is a representative of this class of bacteria.
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Dihydroneopterin aldolase (DHNA) catalyzes the conver-
sion of 7,8-dihydroneopterin (DHNP) to 6-hydroxymethyl-
7,8-dihydropterin (HP) with the generation of glycoaldehyde
[1] (Figure 1). This is a committing step in the folate path-
way because HP is the first compound in the pathway
used only for the biosynthesis of folate cofactors. DHNA
functions as a homooctamer. The enzyme is a unique
aldolase in that it requires neither metal ions nor the
formation of a Schiff base between the enzyme and the
substrate for catalysis [1]. Furthermore, the enzyme also
catalyzes the epimerization of DHNP to 7,8-dihydromo-
napterin (DHMP) at a significant rate, but the biological
function of DHMP is not clear [2].
Folate cofactors are essential for life [3]. Mammals ob-
tain folates from their diet because they cannot synthesize
folates de novo but have an active transport system. In
contrast, most microorganisms must synthesize folates de
novo because they cannot take folates from their environ-
ments due to the lack of an active transport system [4].
Therefore, the folate biosynthetic pathway has been one of
the principal targets for developing antimicrobial agents
[5-9]. Among the folate pathway enzymes, the four en-
zymes in the mid pathway are particularly attractiveFigure 1 Reaction and sequence of DHNA. (A) Reactions catalyzed by D
sequence alignment of Gram-positive SaDHNA [Swiss-Prot:P56740; PDB:2NM
Secondary structural elements are outlined with boxes. The conserved ami
while the sequence variations that have significant impact on ligand bindinbecause they are absent in mammals: DHNA, 6-hydroxy-
methyl-7,8-dihydropterin pyrophosphokinase (HPPK),
dihydropteroate synthase (DHPS), and dihydrofolate
synthase (DHFS). DHPS is the target of sulfa drugs, the
clinical use of which marks the beginning of the modern
era of antimicrobial chemotherapy [10]. The multiple tar-
gets afforded by this pathway also provide opportunities
to develop antibiotics with synergetic effects. For example,
in clinical use, sulfonamides, which target DHPS, are com-
bined with trimethoprim, an antibiotic targeting DHFS,
the last enzyme in the folate pathway [10].
Interestingly, DHNAs from Gram-positive and Gram-
negative bacteria have some unique sequence motifs [11].
The sequence identities between enzymes from Gram-
positive bacteria range from 39% to 45% and those
between Gram-negative bacteria are 49-91%, but the
identities between Gram-positive and Gram-negative
bacterial enzymes are <30% [11]. Many differences between
the amino acid sequences of DHNAs from Gram-positive
and Gram-negative bacteria are at or near the active center.
In accordance with the significant differences between their
sequences, biochemical studies have shown that EcDHNA
and SaDHNA have significantly different ligand binding
and catalytic properties [11-13].HNA. (B) Chemical structures of NP and MP. (C) Structure-based
3] and Gram-negative EcDHNA [Swiss-Prot:P0AC16; PDB:2O90].
no acid residues among all DHNA sequences are highlighted in red,
g are indicated with arrows in black.
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DHNAs from Gram-positive bacteria S. aureus [14-16],
Mycobacterium tuberculosis (MtDHNA) [17], Streptococcus
pneumoniae [18], and the plant Arabidopsis thaliana
[19]. The active site of the enzyme has been identified
by the protein-product (HP) structures of SaDHNA
[PDB:2DHN] [14] and MtDHNA [PDB:1NBU] [17]. The
structural information about the critical interactions be-
tween DHNA and the trihydroxypropyl moiety of the sub-
strate, which undergoes bond cleavage and formation, has
been revealed by our structures of SaDHNA in complex
with neopterin (NP) [PDB:2NM2] and with monapterin
(MP) [PDB:2NM3], respectively [16]. NP and MP are
excellent inhibitors for SaDHNA, because the only dif-
ference between these inhibitors and the corresponding
substrates is that the single bond between C7 and N8 in
the substrates is replaced by a double bond in the inhibi-
tors (Figure 1). The crystal structures of SaDHNA in com-
plex with NP or MP have provided important insights
into the catalytic mechanism of the enzyme [16].
No crystal structure has been reported for DHNAs from
Gram-negative bacteria. Because E. coli is a representative
of Gram-negative bacteria and EcDHNA has been well
characterized biochemically [11], we have determined the
crystal structures of EcDHNA in complex with the sub-
strate analogue NP (EcDHNA:NP) [PDB:2O90]. Based
on this crystal structure, we have built an atomic model
of the enzyme in complex with the substrate DHNP
(EcDHNA:DHNP) and performed molecular dynamics
(MD) simulation of the enzyme:substrate complex. The
results provide insights into the mechanism of DHNA
catalysis, the structural basis of biochemical differences
between SaDHNA and EcDHNA, and valuable informa-
tion for structure-based design of novel antimicrobial
agents.
Results
Overall structure of the EcDHNA:NP complex
The EcDHNA:NP structure has been determined at
1.07-Å resolution. The asymmetric unit of the structure
contains one DHNA polypeptide, one NP molecule, and
279 water molecules. Thus, the octamer of EcDHNA:NP
contains eight identical active sites. Seven residues at the
C-terminus (Asn116-Asn122) are not observed and thus
presumably disordered. Met1 exhibits three conforma-
tions of equal probabilities; 20 residues (Ile3, Gln8, Ser10,
Val17, Tyr18, Asp19, Lys27, Asp31, Glu33, Arg39, Ser62,
Arg68, Leu82, Arg93, Ile94, Ser97, Pro99, Gly100, Ala101,
and Glu113) assume two conformations.
Interactions between EcDHNA and NP
The bound NP and its most important interactions with
EcDHNA are illustrated in Figure 2. The trihydroxypropyl
tail of NP assumes two conformations, with the 3′-hydroxylgroup in significantly different positions. NP is sur-
rounded by residues Ile15-Tyr18, Trp20, Glu21, Gln26,
Ala70-Glu73, Lys98, Gly100-Val102, and Val108-Val110
from one subunit and Val4′, Val47′, and Cys50′-Asp55′
from the adjacent subunit (denoted by the prime sym-
bols). The pteridine ring of NP is stacked on the phenol
ring of Tyr53′, and other important interactions include
hydrogen bonds to the side-chain groups of Glu73 and
Ser52′, the main-chain groups of Leu72, Leu51′, and
Tyr53′, and a water molecule (Figure 2). The water mol-
ecule is also hydrogen bonded to the main-chain carbonyl
oxygen of Ala70 and the amino group of Lys98. The 1′-
hydroxyl group of the trihydroxypropyl tail forms one
hydrogen bond each to the main-chain NH of Val17 and
the amino group of Lys98 and a bifurcated hydrogen bond
to the carboxyl group of Glu21. The 2′-hydroxyl group is
hydrogen bonded to both the amino group of Lys98 and
the phenol group of Tyr53′. In one conformation, the 3′-
hydroxyl group is hydrogen bonded to the main-chain
carbonyl oxygen of Ala101, and in the other conformation,
it has no direct interaction with the protein.
Comparison with the SaDHNA structure
The conformation of EcDHNA shows significant differ-
ences in comparison with those of other species. Because
EcDHNA and SaDHNA are the best characterized among
DHNAs [2,11,13,14,16] and, furthermore, E. coli and S.
aureus are representatives of Gram-negative and Gram-
positive bacteria, respectively, we compared the structures
of these two enzymes. The root-mean-square deviation for
main-chain atoms (RMSD) between the EcDHNA in the
asymmetric unit of EcDHNA:NP and the four SaDHNA
polypeptide chains in the asymmetric unit of SaDHNA:
NP ranges 1.03-1.09 Å. The most significant differences
are found between the active sites of the two enzymes
(Figure 3A), particularly in the loop that connects strands
β3 and β4. The conformational difference in the loop is
obviously due to the significant sequence differences in
this region (Figure 1). In SaDHNA, it consists of 11 resi-
dues, including three prolines, whereas in EcDHNA, it
contains nine residues, including only one proline. The
significance of these conformational differences will be
discussed below.
The functional assembly of DHNA is an octamer,
which consists of two stacked doughnut-shaped tetra-
mers. The RMSD between the functional octamers of
EcDHNA and SaDHNA reaches 1.67 Å, which is sub-
stantially larger than those between two single sub-
units. The large RMSD is due to the difference in the
packing between the two tetramers (Figure 3B), which
is mainly due to an 8° rigid body rotation. The indole
rings of the Trp20 residue in one tetramer stack on
those of the corresponding Trp residues in the other
tetramer (not shown), and therefore, the Trp substitution,
Figure 2 Stereoview showing the active center structure of EcDHNA:NP. The 2Fo - Fc electron density (net in purple) contoured at 2.5 σ for
the NP molecule and at 1.2 σ for the disordered portion of the trihydroxypropyl moiety (net in gray). Residues colored in blue are from the
symmetry-related molecule that forms the active center with the primary molecule. The illustration was made using MolScript [20].
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stabilizing the EcDHNA octamer.
Biochemical studies have shown that the kinetic param-
eters for EcDHNA and SaDHNA are significantly different
[11]. Among many sequence variations, seven amino acid
substitutions (Figure 1C) occur in the vicinity of the active
site, among which two are shown in Figure 4, Tyr18 and
Ser52 in EcDHNA, corresponding to Leu19 and His53 in
SaDHNA, respectively. These two substitutions may have
greatest impact on the binding properties of the enzymes.
The combination of Leu19 and His53 in SaDHNA result
in a wide open exit to the active site, whereas the Tyr18
and Ser52 in EcDHNA, especially Tyr18, largely block the
active-site exit (Figure 5). Furthermore, the hydroxyl
group of Ser52 can form a hydrogen bond with reduced
or oxidized pterin compounds, because the hydroxyl
group can function as either a hydrogen bond donor or an
acceptor. The hydrogen bond between the hydroxyl of
Ser52 and an oxidized pterin compound may be even
stronger than that with the corresponding reduced pterin
compound, because the Kd value of EcDHNA for the
oxidized HP is significantly lower than that for HP [11].
The Kd values of SaDHNA for the paired pterin com-
pounds are the same [11], because the group at position 8
of the pteridine moiety has no hydrogen bond interaction
with the protein [14]. These structural features are con-
sistent with the significantly lower Kd values for the bind-
ing of NP, MP, HP, and oxidized HP by EcDHNA when
compared with the Kd values for the binding of these
ligands by SaDHNA [11]. In particular, the Kd value of
SaDHNA for oxidized HP (24 μM) is 240 times that of
EcDHNA (0.10 μM). The lower Kd values of EcDHNA for
the pterin compounds are due to smaller dissociation
rate constants [11]. The dissociation rate constant forthe product HP is only 0.26 s-1, which is the rate-limiting
step in the EcDHNA-catalyzed conversion of DHNP to
HP, whereas the corresponding dissociation rate constant
in the SaDHNA-catalyzed reaction is 14 s-1. The slower
dissociation of the product HP in EcDHNA is probably
due to the need of breaking the additional hydrogen bond
with the hydroxyl group of Ser52 and the obligatory
movement of the Tyr18 phenol ring.
Dynamic properties of the enzyme-substrate complex
EcDHNA:DHNP
Because many residues at or near the active center assume
multiple conformations in the high-resolution EcDHNA
crystal structure, we were interested in and investigated
the dynamic properties of the enzyme-substrate complex
EcDHNA:DHNP by MD simulation. The MD trajectory
of the 27-ns MD simulation is stable, with the RMSD
from the crystal structure rising quickly to ~1 Å and stabi-
lized at ~1.6 Å (Figure 6, panel 9). The magnitude of the
RMSD of the 27-ns MD simulation of the EcDHNA-
substrate complex is similar to those of the 2-ns MD sim-
ulations of the apo SaDHNA and the SaDHNA-product
complex [23].
To assess whether the motions of individual protomers
are independent, we calculated the RMSD of each pro-
tomer (Figure 6). The RMSD plots of protomers 3, 5,
and 7 are similar, rising quickly to and staying at ~1 Å.
The RMSD plots of protomers 6 and 8 are similar, with
the RMSD values increasing in two stages, first rising to
and staying at ~1 Å and then rising to and staying at ~2 Å.
It is worthy to note that the transition between these two
stages is different for the two protomers, with one much
earlier than the other. The RMSD plots of the other three
protomers are in between. The differences in the RMSD
Figure 3 Folding and packing comparison between EcDHNA:NP and SaDHNA:NP. (A) Folding comparison between the two structures.
(B) Packing comparison between the two structuers. In panel A, EcDHNA and SaDHNA are in magenta and cyan, respectively. In panel B, the two
tetramers of EcDHNA are in magenta and red, and those of SaDHNA are in cyan and green. The illustration was made using MolScript [20] and
Raster3D [21,22].
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tions of individual protomers are largely independent, in
consistence with the uncooperative binding of NP and
DHNP to the enzyme observed in biochemical experiments
[11]. Consequently, the analyses of the MD data are based
on the behaviors of individual protomers rather than the
octomer as a whole. The MD data are effectively composedof eight 27-ns trajectories, equivalent to an aggregate simu-
lation time of 216 ns, and the results below are the average
of the eight trajectories.
The flexibility of EcDHNA is assessed by the analysis
of the Cα root-mean-square fluctuation (RMSF) of each
residue (Figure 7) calculated based on the superposition
of individual protomers as we have done in the analysis
Figure 4 Stereoview showing the active site comparison between EcDHNA:NP and SaDHNA:NP. The NP molecules and amino acid
residues are shown as stick models in atomic color scheme (carbon in green for EcDHNA and in cyan for SaDHNA, nitrogen in blue, and oxygen
in red). The illustration was made using PyMOL (Delano Scientific, San Carlos, CA, USA).
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RMSF from the MD simulation at 300 K is significantly
larger than that from the B factors of the crystal structure
derived from the diffraction data obtained at 100 K,
suggesting that the protein is much more flexible than
indicated by the crystallographic B factors. Based on
the RMSF analysis, two long regions of residues show
significant flexibility, residues 16-24 and 35-53, the
functional significance of which will be discussed in a
later section. Besides the terminal residues, additional
residues with significant motion include residues 65-70,
85-91, and 99-106.
The flexibility of EcDHNA is further characterized by
Principal component analysis (PCA) to identify the dom-
inant modes of fluctuation. The results show that the
first three modes accounts for 52.5% of total fluctuation,
the first five modes account for 63.8%, and the first ten
modes account for 74.8%, indicating that the major mo-
tions of EcDHNA can be described by the first several
modes of fluctuation. Figure 8A shows the Cα atom RMSF
projections onto the first three principal component ei-
genvectors. It is clear that motion in the first principalFigure 5 Molecular surface representations for the active site in the E
the EcDHNA:NP complex. (B) Active site structure in the SaDHNA:NP comp
shown as stick models in atomic color scheme (carbon in green for EcDHN
side-chains are also highlighted with transparent atomic surfaces. The illustcomponent mode (vector 1) is dominated by residues
38-53; motion in the second principal component mode
(vector 2) dominated by residues 15-25, 38-53, and 65-70;
and motion in the third principal component mode
(vector 3) dominated again by residues 38-53. Since the
motion of residues 38-53 are prominent in all three princi-
pal component modes and these principal component
vectors are orthogonal, these residues must have complex
motional behavior. To illustrate this complex motional be-
havior, we grouped the snapshots of the whole trajectory
into five clusters as illustrated in Figure 8B. The represen-
tatives of the five clusters are very similar to each other
except the region encompassing residue 38-53. Even the
small α-helix (residue 37-45) within this region shows
different conformations among those representative struc-
tures: It can shorten or bend.
Interactions between the substrate DHNP and the enzyme
Since hydrogen bond interactions are important for not
only substrate binding but also catalysis by DHNA, we
focused our analysis of the interaction between the sub-
strate and the enzyme on hydrogen bonds. The resultscDHNA:NP and SaDHNA:NP complexes. (A) Active site structure in
lex. The NP molecules and two variable amino acid side-chains are
A and in cyan for SaDHNA, nitrogen in blue, and oxygen in red). The
ration was made using PyMOL (Delano Scientific, San Carlos, CA, USA).
Figure 6 RMSD (for main-chain atoms) of individual EcDHNA protomers in MD simulation of the enzyme:substrate complex. The first
eight panels are the RMSD of eight EcDHNA protomers based on the superposition of individual protomers. Panel 9 is the RMSD of the EcDHNA
octamer based on the superposition of the octamer.
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The hydrogen bonds between the substrate DHNP and
the enzyme EcDHNA suggested by the MD simulation
are largely similar to those between the inhibitor NP and
the enzyme EcDHNA in the crystal structure, indicating
that the inhibitor NP is a good mimic of the substrate
DHNP and the MD simulation indeed reflects the dynam-
ics of the enzyme. However, the MD simulation data also
provide some significant new information about the inter-
actions between the substrate and the enzyme. First, the
hydroxyl group of Ser52′ functions as a donor and forms
a hydrogen bond with 8-NH of DHNP. Second, the hydro-
gen bond corresponding to that between 3′-hydroxyl of
the inhibitor and the enzyme in the crystal structure is
essentially nonexistent in the MD trajectory of the
enzyme-substrate complex, observed in only 7.33% of
the snapshots of the MD trajectory. Finally, some
hydrogen bonds are much more persistent or stable than
others. The most persistent hydrogen bonds between the
substrate and the enzyme are those of the substrate with
the carboxylate of Glu73 and the backbone amides ofLeu51′ and Leu72, observed in >95% of the snapshots of
the MD trajectory. The hydrogen bond between N1 of
DHNP and the backbone NH of Tyr53′ is weak, with an
occurrence of only ~16%. Based on the hydrogen bond oc-
currence data (Table 1), the pterin portion of the substrate
is fixed in the active site, the 1′- and 2′-hydroxyl groups
have some motions, and the 3′-hydroxyl group is flexible.
The flexibility of 3′-hydroxyl allows both DHNP and
DHMP to serve as substrates for the enzyme.
Discussion
Insights into substrate binding and catalysis
DHNA is a special aldolase because it does not require a
zinc ion or the formation of a Schiff base between the
enzyme and the substrate for catalysis and generates an
epimerization product at a significant rate. The hallmark
of its catalytic power is general acid/base catalysis. Two
proton wires have been proposed for DHNA catalysis
[16]. The first proton wire consists of a conserved Lys
residue, a catalytic water molecule, and 2′-OH and N5
of the substrate DHNP. This proton wire is revealed by
Figure 7 RMSF of the Cα atoms of EcDHNA. Black, calculated from the trajectory of the MD simulation of the substrate complex; red,
calculated from the B factors of the crystal structure of the inhibitor complex for comparison.
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[PDB:2NM2] and is required for the cleavage of the
C1′-C2′ bond, which generates the enol intermediate.
The importance of the conserved Lys residue, Lys98
in EcDHNA, for catalysis has been demonstrated byFigure 8 Principal component and clustering analyses. (A) Projection o
representative structures from cluster analysis. The segment of the protein
and ending residue numbers.site-directed mutagenesis. The second proton wire con-
sists of a conserved Tyr residue, Tyr53 in EcDHNA, the
conserved Lys residue, the catalytic water, and C1′ and
N5 of the reaction intermediate. This proton wire is pro-
posed based on a mutagenesis study of the conserved Tyrf Cα-atom RMSF in the first three principal components. (B) Overlay of
with the largest deviation in panel B is labelled with the beginning
Table 1 Hydrogen bonds between DHNP, the catalytic




Leu72 − NH…O = C4 99.73 2.91 ± 0.14 2.94
WAT −OH… O = C4 82.2 2.94 ± 0.20 2.79
Glu73 −OE1…H − N3 100 2.79 ± 0.09 2.76
Glu73 −OE2…H − NC2 99.74 2.84 ± 0.13 2.73
Leu51′ − O…H − NC2 95.94 2.93 ± 0.15 2.85
Tyr53′ − NH…N1 16.04 3.33 ± 0.12 2.98
WAT −OH…N5 70.61 3.18 ± 0.19 3.31
Ser52′-OG…H − N8 88.82 3.03 ± 0.17 NAb
Glu21 −OE1…H −OC1′ 80.59 2.69 ± 0.24 2.64
Val17 − NH…OC1′ 80.15 2.98 ± 0.20 2.88
Lys98 − NZ… H −OC2′ 76.54 2.95 ± 0.16 2.75
Tyr53′ −OH…OC2′ 63.96 3.10 ± 0.19 2.61
Ala101 − O…H −OC3′ 7.33 3.00 ± 0.24 2.90
Lys98 − NZH…WAT 91.5 2.98 ± 0.17 2.87
aThe corresponding hydrogen bonds in the crystal structure of EcDHNP:NP are
listed for comparison. bNA, not applicable.
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that the Tyr residue is not required for the generation of
the reaction intermediate but for protonation of it to
generate the product HP. The first proton wire is
present in the crystal structure of EcDHNA in complex
with NP and the atomic model of the complex of
EcDHNA and the substrate DHNP reported here. The
formation of the second proton wire needs significantFigure 9 Hydrogen bonding between substratrate and enzyme obser
Hydrogen bonds are shown in dashed lines. Only hydrogen bonds with lar
how DHNP is cleaved into HP and GA is presented in Figure 1A.local conformational adjustment. In consistence with this
requirement, the segment of the protein containing Tyr53
(residues 38-53) is most flexible in the MD simulation
with the highest RMSF. This flexibility may also allow the
rotation of the product glycoaldehyde and generation of
the epimerization product MP.
The MD simulation of the EcDHNA complex also
shows that the substrate DHNP is anchored in the active
site by four hydrogen bonds between the substrate (the
groups at positions 2, 3, and 4) and the protein (backbone
amides of Leu51′ and Leu72 and carboxylate of Glu73).
This is manifested by the persistence of these hydrogen
bonds, found with >95% of the snapshots of the MD simu-
lation. Particularly, the carboxylate of Glu73 forms two
hydrogen bonds, one with 1-NH and the other with 2-
NH2, the former with a 100% of occurrence and the latter
with a 99.7% of occurrence. Indeed, mutagenesis studies
have shown that Glu73 is the most important residue for
binding of the substrate DHNP, the inhibitor NP, and the
product HP. In contrast, the hydrogen bonds between the
trihydroxyl moiety of DHNP and the protein are transient,
with occurrence in the range of 7.3 − 80.6%. In particular,
the hydrogen bond between 3′-OH of the substrate and
the backbone amide of Ala101 observed in the crystal
structure is largely absent in the MD simulation, with an
occurrence of only 7.3%. The transient nature of these
hydrogen bonds, particularly the rare occurrence of the
hydrogen bonding of 3′-OH, may allow the epimer DHMP
serve as a good substrate as demonstrated by biochemical
analysis [11].
The asynchronous motions of individual protomers
observed in the MD simulation are also biochemicallyved in MD simulation of the enzyme:substrate compplex.
ger than 50% occurrence were drawn. A schematic diagram showing
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tein, it does not show cooperativity in binding substrate
or other ligands. This lack of cooperativity is consistent
with the asynchronous motions of individual protomers
in the MD simulation.
Implications for structure-based drug design
Infectious diseases are the leading causes of death and
the main causes of premature death (0-44 years) [24].
Widespread and persistent antibiotic resistance has
caused a worldwide health care crisis [5,25,26]. The
crisis has been aggravated by the decisions by many
major pharmaceutical companies to abandon or curtail
their antibacterial programs for business reasons [27-29]
and the fact that most new antibiotics are chemical modi-
fications of existing antimicrobial agents [30]. These com-
pounds act against old targets and are therefore less
effective in dealing with widespread antibiotic resistance.
New targets for the development of novel antimicrobial
agents are thus urgently needed for combating the anti-
biotic crisis.
DHNA is an attractive target for developing new anti-
biotics, because the enzyme is in a biosynthetic pathway
proven effective in developing antibiotics and is absent
in human. Sanders and coworkers have reported the
development of inhibitors against SaDHNA [15]. The
fact that EcDHNA and SaDHNA have significant differ-
ences in their biochemical properties and active center
structures, structure-based drug design must take into
account the structure of EcDHNA for developing broad-
spectrum antibiotics. On the other hand, DHNAs from
Gram-negative bacteria are highly homologous, and so
their active centers are expected to have very similar
shapes and physicochemical characteristics. The structure
of EcDHNA reported here offers an opportunity to de-
velop antibiotics specific for Gram-negative bacteria.
Conclusions
The EcDHNA:NP structure has been determined at
1.07 Å, the highest resolution among all of the DHNA
structures reported to date. This crystal structure of the
inhibitor complex and the MD simulation of the substrate
complex EcDHNA:DHNP have provided important in-
sights into substrate binding and catalysis. The substrate
DHNP is anchored in the active site via four persistent
hydrogen bonds. The transient nature of hydrogen bond-
ing between the trihydroxyl moiety and the protein and
the rare occurrence of hydrogen bonding with 3′-hydroxyl
allow the pair of epimers DHNP and DHMP to serve as
good substrates. The high flexibility of segments of the
protein, particularly residues 38-53, may permit the
switching from the first to the second proton wire during
catalysis and the generation of the epimerization product.
The asynchronous motions of individual protomers areconsistent with the noncooperative binding of the sub-
strate by DHNA. Between EcDHNA and SaDHNA, the
two best characterized DHNAs, there are three out-
standing structural differences. First, the packing of
the two tetramers in the EcDHNA octamer is signifi-
cantly different from that in the SaDHNA octamer due
to a single mutation. Residue Trp20 in EcDHNA is an
Ala in SaDHNA. The indole rings of the Trp20 residue
in one tetramer stack on those of the corresponding
Trp residues in the other tetramer, stabilizing the
EcDHNA octamer. Second, the active site structures of
the two enzymes, especially in the β3-β4 loop, are signifi-
cantly different due to the difference in amino acid se-
quences. In SaDHNA, the loop is 11 residues in length,
including three prolines, whereas in EcDHNA, it has nine
residues, containing only one proline. Third, the entrance
to the active site is significantly different in the two en-
zymes. The combination of Leu19 and His53 in SaDHNA
result in a wide open entrance, whereas the Tyr18 and
Ser52 in EcDHNA largely block the entrance. These
structural differences provide the basis for the bio-
chemical differences between the S. aureus and E. coli




Cloning, expression, and purification of EcDHNA have
been reported previously [11]. NP was purchased from
the Schircks Laboratories. The crystals of EcDHNA:NP
were obtained via co-crystallization using the hanging-drop
technique at well-controlled room temperature (19 ± 1°C).
The protein solution was mixed and incubated with the
ligand prior to crystallization experiments. The drops con-
tained equal volumes of protein and reservoir solutions.
The protein solution contained 11 mg/mL protein and
25 mM NP in 10 mM Tris-HCl (pH 8.0). The well solution
contained 4.0 M sodium formate (pH 7.0). Crystals reached
the size of 0.25 × 0.35 × 0.60 mm in about three months.
The crystal was tetragonal (I422) and diffracted to
1.07-Å resolution. X-ray diffraction data were collected
from a single crystal at 100 K with an ADSC Quantum-
4 CCD detector mounted on the synchrotron beamline
X9B at National Synchrotron Light Source, Brookhaven
National Laboratory. Data processing was carried out with
HKL2000 [31]. Data collection and processing details are
summarized in Table 2.
The structure was solved by molecular replacement
(MR) using the apo-DHNA structure [PDB:1DHN] as the
search model after the solvent molecules were removed.
The MR solutions were subjected to rigid body refinement,
energy minimization, and grouped B-factor refinement
followed by a difference Fourier synthesis, which revealed
the locations of the ligand molecule.
Table 2 X-ray data and refinement statistics for the
EcDHNA:NP structure [PDB:2O90]
Data Overall Last shell
Resolution range (Å) 30.0-1.07 1.11-1.07





Refinement All data I ≥ 2σ(I)
Reflections used for refinement 53895 45617
Reflections used for Rfree 2832 2390
Number of least-squares parameters 9680




Number of protein atoms/average B factor (Å2) 1001/13.3
Number of ligand atoms/average B factor (Å2) 23/13.2
Number of water oxygen atoms/average B
factor (Å2)
279/37.5
RMSD from ideal geometry:
Bond distances (Å) 0.019
Angle distances (Å) 0.034
Ramachandran plot:
Most favored φ/ψ angles (%) 97.2
Disallowed φ/ψ angles (%) 0.0
aRscaling = Σ|I- < I > |/ΣI.
bCrystallographic R = Σhkl | |Fo| - |Fc| | / Σhkl |Fo|.
cRfree is calculated from 5% of data randomly chosen and not included
in refinement.
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stage and SHELXL [33] till completion. Model building
was carried out using the graphics package O [34]. The
structure was refined with anisotropic temperature factors
for non-hydrogen atoms, except for regions of increased
mobility where the temperature factors were refined
isotropically. For atoms with anisotropic temperature
factors, the hydrogen atoms were built at idealized
positions, with assigned isotropic temperature parameters
equal to 1.2 times the equivalent isotropic temperature
parameters of their parent atoms. Positional parame-
ters of ligands have been refined with geometric re-
strictions for bond lengths, bond angles and planarity.
The geometry of the final structure was assessed using
PROCHECK [35] and WHAT IF [36]. The asymmetric
unit of EcDHNA:NP contains residues 1-115 of the
DHNA polypeptide chain (122 residues), one NP mol-
ecule, and 263 water molecules. The details of structure
refinement and the statistics of the final structure are
summarized in Table 2.
Atomic coordinates and structure factors have been
deposited with the Protein Data Bank under accession
codes 2O90.Molecular dynamics simulations
The PMEMD module of the Amber molecular dynamics
package (version 10) [37] and the Amber ff03 force field
[38] were used for the MD simulation of the EcDHNA:
DHNP complex. RESP charges for DHNP were derived
by using the Antechamber module of Amber 10 with
DHNP optimized and its molecular electrostatic poten-
tial calculated using the Gaussian program (version 03)
[39] at the HF/6-31G* level. The starting coordinate was
the crystal structure of EcDHNA:NP with NP replaced
by DHNP. All the crystallographic water molecules were
removed except the one which is hydrogen bonded to
N5 of NP and the amino group of Lys98. The side chain
of Lys98 was in the deprotonated form as deemed to be
the active form. The protonation and tautomerization
states of the histidine residues were assigned taking into
account their hydrogen bond interactions in the crystal
structure. The default protonation states were used for
all of the other amino acids. The system was solvated by
a periodic box of TIP3P water molecules that extended
at least 12 Å from the protein atoms and neutralized by
the addition of Na+ ions. The solvent and Na+ ions were
subjected to energy minimization by 1000 steps steepest
descent followed by 1500 steps conjugated gradient
minimization while both the protein and DHNP were
restrained harmonically with a force constant 50.0 kcal/
mol/Å2. The MD simulation was run at constant vol-
ume for 200 ps to heat up the system from 0 to 300 K
while the solutes were restrained in the same way as in the
energy minimization, and then at constant temperature and
pressure, which were regulated by Langevin dynamics
and isotropic position scaling, respectively. The SHAKE
algorithm was used to constrain all bond lengths involv-
ing hydrogen atoms, permitting a 2-fs time step [40].
The Particle-Mesh-Ewald method was used to evaluate
the contribution of long-range electrostatic interactions
[41]. A non-bonded pair list cut off 12.0 Å was used,
and the list updated every 25 steps. Coordinates were
saved every 2 ps. PCA of the MD trajectory was carried
out using the program GROMACS 3.2 [42,43]. The
overall translational and rotational motions for all snap-
shots were removed, and the covariance matrix for all
Cα atom fluctuations from their trajectory-averaged values
was calculated. The conformational clustering was based
on the RMSD for main-chain atoms using the average-
linkage algorithm as implemented in the PTRAJ module
of Amber 10 as previously described [23].
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